Vitamin D deficiency promotes prostate cancer growth in bone

Prostate

Volumn 71, Issue 9, 2011, Pages 1012-1021

  Zheng, Yu ^a   Zhou, Hong ^a   Ooi, Li Laine ^a   Snir, Afik D ^a   Dunstan, Colin R ^a,b   Seibel, Markus J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

bone metastasis; cancer growth; osteoclasts; prostate cancer; vitamin D deficiency

Indexed keywords

OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METABOLISM; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN PC3; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN CELL; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; VITAMIN D DEFICIENCY;

ACID PHOSPHATASE; ANIMALS; BONE NEOPLASMS; BONE REMODELING; CALCITRIOL; CELL LINE, TUMOR; HISTOCYTOCHEMISTRY; ISOENZYMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSTATIC NEOPLASMS; SPECIFIC PATHOGEN-FREE ORGANISMS; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 79955598411     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21316     Document Type: Article

References (33)

1. Mundy GR,. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2 (8): 584-593. (Pubitemid 37328925)
2. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET,. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107 (10): 1235-1244. (Pubitemid 32494540)
3. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, Dunstan CR,. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40 (2): 471-478. (Pubitemid 46070226)
4. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ,. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61 (11): 4432-4436. (Pubitemid 32685771)
5. Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ,. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: Model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003; 107 (3): 468-477. (Pubitemid 37266469)
6. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK,. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146 (4): 1727-1736. (Pubitemid 40396881)
7. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW,. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005; 65 (11): 4929-4938. (Pubitemid 40740833)
8. Hirbe AC, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K,. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood 2007; 109 (8): 3424-3431. (Pubitemid 46572532)
9. Zheng Y, Zhou H, Modzelewski JR, Kalak R, Blair JM, Seibel MJ, Dunstan CR,. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 2007; 67 (19): 9542-9548. (Pubitemid 47535945)
10. Zheng Y, Zhou H, Fong-Yee C, Modzelewski JR, Seibel MJ, Dunstan CR,. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis 2008; 25 (5): 559-567.
11. Lagunova Z, Porojnicu AC, Dahlback A, Berg JP, Beer TM, Moan J,. Prostate cancer survival is dependent on season of diagnosis. Prostate 2007; 67 (12): 1362-1370. (Pubitemid 47435784)
12. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M,. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004; 108 (1): 104-108. (Pubitemid 37444451)
13. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB,. Serum vitamin D concentration and prostate cancer risk: A nested case-control study. J Natl Cancer Inst 2008; 100 (11): 796-804. (Pubitemid 351809669)
14. Peleg S, Khan F, Navone NM, Cody DD, Johnson EM, Van Pelt CS, Posner GH,. Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3. J Steroid Biochem Mol Biol 2005; 97 (1-2): 203-211. (Pubitemid 41546230)
15. Peng X, Hawthorne M, Vaishnav A, St-Arnaud R, Mehta RG,. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat 2009; 113 (1): 31-41.
16. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M,. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 2005; 11 (9): 3579-3586. (Pubitemid 40627915)
17. Cross HS, Lipkin M, Kallay E,. Nutrients regulate the colonic vitamin D system in mice: Relevance for human colon malignancy. J Nutr 2006; 136 (3): 561-564. (Pubitemid 43363735)
18. Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C, Berciano MT, Lafarga M, Munoz A,. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007; 75 (3): 193-207. (Pubitemid 46426618)
19. Rohan JN, Weigel NL,. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009; 150 (5): 2046-2054.
20. Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, Seibel MJ, Dunstan CR,. Vitamin d deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res 2010; 70 (5): 1835-1844.
21. Bult P, Manders P, Straatman HM, Tjan-Heijnen VC, Beex LV, Hendriks J, Leer JW, Verbeek AL, Holland R,. In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade: A study with long-term follow-up. Breast Cancer Res Treat 2010; 122 (1): 77-86.
22. Mehta RR, Graves JM, Hart GD, Shilkaitis A, Das Gupta TK,. Growth and metastasis of human breast carcinomas with Matrigel in athymic mice. Breast Cancer Res Treat 1993; 25 (1): 65-71. (Pubitemid 23107737)
23. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF,. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96 (2): 252-261. (Pubitemid 43167123)
24. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N,. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27 (23): 3757-3763.
25. Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M,. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 2001; 47 (4): 686-693. (Pubitemid 32275812)
26. Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J, Lipton A,. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004; 15 (3): 455-459. (Pubitemid 38444549)
27. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE,. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97 (1): 59-69.
28. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR,. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006; 12 (11 Pt 1): 3361-3367.
29. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET,. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 2008; 68 (14): 5785-5794.
30. Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E,. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004; 21 (5): 381-387.
31. Holick MF,. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging 2007; 24 (12): 1017-1029. (Pubitemid 350145410)
32. Vieth R, Chan PC, MacFarlane GD,. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73 (2): 288-294. (Pubitemid 32109858)
33. Peterlik M, Cross HS,. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 2005; 35 (5): 290-304. (Pubitemid 40675603)